Business
Director Dealings
Director Dealings.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0193S\n Allergy Therapeutics PLC\n 11 November 2021\n \n \n \n \n \n \n \n \n \n \n Allergy Therapeutics plc\n \n \n \n \n \n (\"Allergy Therapeutics\" or the \"Company\")\n \n \n \n \n \n Director Dealings\n \n \n \n \n \n 11 November 2021 \n - Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that \n Peter Jensen, Non-Executive Chairman, has purchased 30,000 ordinary shares of 0.1 pence each in the capital of the Company (\"Ordinary Shares\") at a price of 36 pence per Ordinary Share. Following the transaction, the total beneficial interest of Peter Jensen is 300,000 Ordinary Shares, representing 0.05% of the of the issued share capital of the Company to which voting rights are attached.\n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n Allergy Therapeutics\n \n \n +44 (0) 1903 845 820\n \n \n Manuel Llobet, Chief Executive Officer\n \n \n Nick Wykeman, Chief Financial Officer\n \n \n \n \n \n Panmure Gordon\n \n \n +44 (0) 20 7886 2500\n \n \n Freddy Crossley, Emma Earl, Corporate Finance\n \n \n Rupert Dearden, Corporate Broking\n \n \n \n \n \n Consilium Strategic Communications\n \n \n +44 20 3709 5700\n \n \n Mary-Jane Elliott, David Daley, Davide Salvi, Alex Gunter\n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n Notes for editors:\n \n \n \n \n \n About Allergy Therapeutics\n \n \n \n \n \n Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.\n \n \n \n \n \n Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 ...